MedVellum
MedVellum
Back to Library

Pediatric Asthma Exacerbation

On This Page

Overview

Pediatric Asthma Exacerbation

Quick Reference

Critical Alerts

  • Silent chest is ominous: No wheezing may mean severe obstruction
  • Hypoxia is a late sign: Respiratory fatigue and hypercapnia precede
  • Magnesium for severe asthma: 40-75 mg/kg IV (max 2g)
  • Continuous albuterol for severe cases: Not just PRN
  • Early steroids reduce admissions: Give within 1 hour
  • Don't delay intubation if indicated: But try to avoid

Key Diagnostics

TestFindingSignificance
SpO2<92% on room airSevere exacerbation
Peak flow<50% predictedSevere exacerbation
Respiratory rateAge-appropriate elevationSeverity marker
Work of breathingRetractions, accessory musclesSeverity marker
Mental statusAgitation → lethargyImpending failure

Emergency Treatments (Pediatric Dosing)

InterventionDoseNotes
Albuterol nebulizer2.5-5 mg q20min × 3, then hourlyOr continuous 0.5 mg/kg/hr
Ipratropium250-500 mcg q20min × 3Add to albuterol for severe
Prednisolone/Prednisone1-2 mg/kg PO (max 60 mg)Within first hour
Dexamethasone0.6 mg/kg PO/IM (max 16 mg)Single dose alternative
Magnesium sulfate40-75 mg/kg IV (max 2g)For severe, over 20 min
Epinephrine IM0.01 mg/kg (1:1000), max 0.3-0.5 mgImpending respiratory failure

Definition

Overview

Acute asthma exacerbation in children is an episode of progressive worsening of asthma symptoms including cough, wheeze, chest tightness, and dyspnea, accompanied by decreased expiratory airflow. It ranges from mild exacerbations manageable at home to severe, life-threatening attacks requiring intensive care.

Classification by Severity

GINA/EPR-3 Severity Assessment:

SeveritySymptomsSpO2Peak FlowRespiratory Rate
MildDyspnea with activity; speaks sentences≥95%≥70%Normal to mildly elevated
ModerateDyspnea at rest; speaks phrases91-94%40-69%Elevated
SevereDyspnea at rest; speaks words only<90%<40% or unableMarkedly elevated, accessory muscles
Life-threateningExhausted, confused, silent chest<90%UnableVariable, may be decreasing (fatigue)

Age-Appropriate Respiratory Rate:

AgeNormal RRElevated RR
<2 months<60>0
2-12 months<50>0
1-5 years<40>0
6-12 years<30>0
>2 years<20>0

Epidemiology

  • Prevalence: 8-10% of children in US have asthma
  • ED visits: 1.8 million/year (age <18)
  • Hospitalizations: 130,000/year
  • Deaths: ~170 deaths/year in children
  • Risk factors for death: Prior intubation, recent hospitalization, low socioeconomic status, poor adherence

Etiology/Triggers

Common Triggers:

CategoryTriggers
InfectionsViral URI (most common—RSV, rhinovirus, influenza)
AllergensDust mites, pet dander, pollen, mold
IrritantsSmoke, pollution, strong odors
ExerciseExercise-induced bronchoconstriction
WeatherCold air, humidity changes
MedicationsNSAIDs, beta-blockers (rare in children)
EmotionsStress, strong emotions

Pathophysiology

Mechanism of Asthma Exacerbation

  1. Trigger exposure: Viral infection, allergen, irritant
  2. Airway inflammation: Mast cells, eosinophils, T-lymphocytes
  3. Bronchial smooth muscle constriction: Bronchoconstriction
  4. Mucus hypersecretion: Airway plugging
  5. Airway edema: Mucosal swelling
  6. Airflow obstruction: Wheeze, air trapping, hyperinflation
  7. V/Q mismatch: Hypoxemia
  8. Respiratory muscle fatigue: Hypercapnia (late)

Physiological Changes

ChangeEffect
Increased airway resistanceDyspnea, wheeze
Air trappingHyperinflation, decreased tidal volume
Increased work of breathingMuscle fatigue, accessory muscle use
V/Q mismatchHypoxemia
Respiratory muscle fatigueHypercapnia, respiratory failure

Why Silent Chest is Dangerous

  • Severe obstruction → negligible airflow
  • No airflow = no wheeze
  • Indicates impending respiratory failure

Clinical Presentation

Symptoms

Typical:

Prodrome (May precede by hours to days):

History

Key Questions:

Physical Examination

Vital Signs:

FindingInterpretation
TachypneaWork of breathing
TachycardiaHypoxemia, catecholamines, albuterol effect
HypoxiaSevere (SpO2 <92%)
Pulsus paradoxus>0 mmHg = severe obstruction

Respiratory Examination:

FindingSeverity
Expiratory wheezeMild-moderate
Inspiratory + expiratory wheezeModerate-severe
Silent chest (no wheeze)Life-threatening
Prolonged expiratory phaseObstruction
Accessory muscle useModerate-severe
Intercostal retractionsSevere
Subcostal retractionsSevere
Nasal flaringSevere
Inability to speak sentencesSevere

Mental Status:

FindingInterpretation
Alert, speaks normallyMild
Anxious, speaks phrasesModerate
Agitated, speaks wordsSevere
Drowsy, confusedLife-threatening

Cough (often worse at night)
Common presentation.
Wheeze
Common presentation.
Dyspnea
Common presentation.
Chest tightness
Common presentation.
Inability to speak full sentences
Common presentation.
History of asthma with similar episodes
Common presentation.
Red Flags

Signs of Impending Respiratory Failure

FindingConcernAction
Silent chestNo airflowImmediate aggressive treatment
Drowsiness, confusionHypercapnia, hypoxiaPrepare for intubation
CyanosisSevere hypoxemiaHigh-flow O2, aggressive treatment
SpO2 <90% despite O2Severe obstructionICU, continuous neb, magnesium
Poor response to initial treatmentRefractoryEscalate therapy
Unable to speakSevere obstructionAggressive treatment
Fatigue, decreased respiratory effortImpending arrestPrepare airway
Prior ICU admission or intubationHigh-risk patientLow threshold for escalation

Differential Diagnosis

Other Causes of Wheezing in Children

DiagnosisKey Features
Bronchiolitis<2 years, viral prodrome, crackles
Viral-induced wheeze<5 years, episodic with viruses, no interval symptoms
Foreign body aspirationSudden onset, unilateral wheeze, choking history
CroupBarky cough, stridor, hoarse voice
AnaphylaxisUrticaria, angioedema, exposure history
PneumoniaFever, crackles, focal findings
PertussisParoxysmal cough, post-tussive vomiting/whoop
Cardiac failureMurmur, hepatomegaly, cardiomegaly
TracheomalaciaRecurrent wheeze, particularly with exertion

Diagnostic Approach

Clinical Assessment

Primary Assessment:

  • Work of breathing
  • Mental status
  • Ability to speak
  • SpO2 on room air
  • Response to initial treatment

Peak Expiratory Flow (If child can perform, usually ≥6 years):

  • Compare to baseline or predicted
  • <50% predicted = severe
  • May not be feasible in severe exacerbation

Scoring Systems

Pediatric Asthma Severity Score (PASS) or Pediatric Respiratory Assessment Measure (PRAM):

  • Standardized assessment of severity
  • Guides therapy escalation

Laboratory Studies

Not routinely required. Consider:

TestIndication
VBG/ABGSevere exacerbation, concern for hypercapnia
CXRSuspected pneumonia, pneumothorax, first episode
Viral panelMay help with cohorting, prognosis

VBG/ABG Interpretation in Asthma:

FindingInterpretation
Low PaCO2 (hyperventilation)Compensated, mild-moderate
Normal PaCO2Concerning—may indicate fatigue
High PaCO2 (hypercapnia)Respiratory failure, impending arrest

When to Image

CXR Indications:

  • Fever + localized findings (pneumonia)
  • First-ever wheeze (consider foreign body, anatomy)
  • Subcutaneous emphysema (pneumothorax/pneumomediastinum)
  • Refractory to treatment
  • Clinical concern for complication

Treatment

Principles of Management

  1. Assess severity: Guide therapy intensity
  2. Bronchodilation: Albuterol ± ipratropium
  3. Systemic steroids: Reduce inflammation
  4. Oxygen: Maintain SpO2 ≥92-94%
  5. Frequent reassessment: Escalate if not improving
  6. Avoid intubation if possible: But don't delay if needed

Bronchodilators

Albuterol (Salbutamol) - First-line:

SeverityDosing
Mild-Moderate2.5-5 mg nebulized q20min × 3, then q1-4h
SevereContinuous nebulization 0.5 mg/kg/hr (max 15 mg/hr)
MDI option4-8 puffs q20min × 3 (with spacer)

Ipratropium Bromide - Add for moderate-severe:

DoseFrequency
250 mcg (<20 kg) / 500 mcg (≥20 kg)q20min × 3 doses, combined with albuterol

Epinephrine IM - Impending respiratory failure or severe bronchospasm: | Dose | 0.01 mg/kg of 1:1000 (max 0.3-0.5 mg) |

Systemic Corticosteroids

Give Within First Hour:

AgentDoseNotes
Prednisolone/Prednisone1-2 mg/kg PO (max 60 mg)3-5 day course
Dexamethasone0.6 mg/kg PO/IM (max 16 mg)Single dose or 2 doses
Methylprednisolone1-2 mg/kg IV (max 125 mg)If unable to take PO

Dexamethasone Advantages: Single dose may be equivalent to 5 days prednisolone; better compliance

Magnesium Sulfate

Indication: Severe exacerbation not responding to initial therapy | Dose | 40-75 mg/kg IV (max 2g) | | Administration | Over 20-30 minutes | | Monitoring | BP, reflexes |

Oxygen Therapy

Goal: SpO2 ≥92-94%

  • Nasal cannula for mild hypoxia
  • Face mask for moderate
  • High-flow nasal cannula for severe
  • Non-rebreather if high O2 requirement

High-Flow Nasal Cannula (HFNC):

  • May reduce work of breathing
  • Consider for severe exacerbation before intubation
  • Rates: 2 L/kg/min for infants; 1 L/kg/min for older children (max 50-60 L/min)

Adjunctive Therapies

TherapyIndicationNotes
HelioxSevere obstruction70:30 or 80:20 He:O2; reduces turbulence
IV terbutalineSevere, failed nebulizers10 mcg/kg bolus, then 0.4-6 mcg/kg/min
IV aminophyllineRarely usedNarrow therapeutic window, many side effects
KetamineSedation for intubationBronchodilating properties
Non-invasive ventilationSelected patientsBiPAP for severe work of breathing

Intubation (Last Resort)

Indications:

  • Respiratory arrest
  • Severe hypoxemia despite aggressive therapy
  • Altered mental status / exhaustion
  • Rising PaCO2 with acidosis

Considerations:

  • Difficult airway (bronchospasm, dynamic hyperinflation)
  • Ketamine is preferred induction agent (bronchodilator)
  • High airway pressures expected
  • Risk of barotrauma
  • Low respiratory rate to allow expiration (permissive hypercapnia)

Treatment Algorithm by Severity

SeverityInitial Treatment
MildAlbuterol q20min × 3, steroids, reassess
ModerateAlbuterol + ipratropium q20min × 3, steroids, O2, reassess
SevereContinuous albuterol, ipratropium, steroids, magnesium, O2, ICU
Life-threateningAll above + prepare for intubation, epinephrine

Disposition

Discharge Criteria

  • Good response to treatment (sustained ≥1 hour after last treatment)
  • SpO2 ≥94% on room air
  • Minimal to no wheeze
  • No retractions
  • Tolerating oral steroids
  • Able to use inhaler properly
  • Family education completed
  • Follow-up arranged (24-72 hours)

Admission Criteria

  • Persistent hypoxia (SpO2 <92% on room air)
  • Persistent respiratory distress after initial treatment
  • Inadequate response to ED treatment
  • Prior ICU admission or intubation (high-risk)
  • Unable to tolerate oral steroids
  • Social concerns, unable to follow up
  • Need for q1-2h bronchodilators

ICU Admission Criteria

  • Severe exacerbation not responding to treatment
  • Need for continuous albuterol
  • Hypercapnia or rising PaCO2
  • Altered mental status
  • Impending respiratory failure
  • Need for intubation

Follow-Up

SituationFollow-Up
Discharged from EDPCP in 24-72 hours
HospitalizedPCP within 1 week; pulm/allergy if recurrent
Multiple ED visitsAsthma specialist referral

Patient Education

Condition Explanation (For Parents)

  • "Your child is having an asthma attack, which means their airways are narrowed and inflamed."
  • "We are giving medicine to open up the airways and reduce the swelling."
  • "It's important to complete the steroid course to prevent the attack from coming back."

Discharge Instructions

  • Complete steroid course (prednisolone for 3-5 days or dexamethasone as prescribed)
  • Continue rescue inhaler as needed (with spacer)
  • Resume controller medications
  • Avoid known triggers
  • Follow up as scheduled

Warning Signs (Return immediately)

  • Worsening breathing difficulty
  • Rescue inhaler not helping
  • Unable to speak or drink
  • Lips or nails turning blue
  • Child becoming very sleepy or confused

Prevent Future Attacks

  • Controller medication adherence (ICS)
  • Avoid triggers
  • Written asthma action plan
  • Influenza vaccination yearly
  • Follow up with primary care/specialist

Special Populations

Infants (<12 months)

  • Diagnosis of asthma uncertain (may be bronchiolitis, viral wheeze)
  • Response to bronchodilators may be less predictable
  • Higher risk for complications
  • Low threshold for admission

Adolescents

  • Adherence issues common
  • Assess for tobacco/vaping/marijuana use
  • Mental health comorbidities
  • Transition planning to adult care

Known High-Risk Patients

  • Prior ICU admission or intubation
  • ≥3 ED visits or ≥2 hospitalizations in past year
  • Recent oral steroid use
  • Poor adherence to controller therapy
  • Significant allergies
  • Low threshold for escalation and admission

Quality Metrics

Performance Indicators

MetricTargetRationale
Time to first bronchodilator<30 minutesRapid treatment
Steroids given within 1 hour>0%Reduce inflammation early
SpO2 documented100%Severity assessment
Discharge with asthma action plan>0%Prevent recurrence
Follow-up within 72h arranged>0%Continuity of care

Documentation Requirements

  • Baseline asthma severity and control
  • Current medications
  • Trigger for exacerbation
  • Physical exam including severity assessment
  • Response to treatment
  • Discharge medications and instructions
  • Follow-up plan

Key Clinical Pearls

Diagnostic Pearls

  • Silent chest = severe obstruction: Not improving, just worse
  • Normal or rising PaCO2 is a red flag: Patient tiring
  • Paradoxical breathing in infants: Sign of fatigue
  • Not all wheeze is asthma: Consider foreign body, cardiac, etc.
  • First wheeze in <12 months: May not be asthma
  • Pulsus paradoxus >20 mmHg: Severe obstruction

Treatment Pearls

  • Steroids within 1 hour: Reduces admissions
  • Continuous nebs for severe: Not PRN
  • Ipratropium only in first hour: No benefit later
  • Dexamethasone 1-2 doses: May equal 5-day prednisolone
  • Magnesium for severe: Give before intubation
  • Ketamine for intubation: Bronchodilator properties

Disposition Pearls

  • Discharge only if sustained improvement: 1+ hour after last treatment
  • Low threshold to admit high-risk patients: Prior intubation, frequent visits
  • Written asthma action plan: Prevents future attacks
  • Follow-up is critical: 24-72 hours

References
  1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention (2023 Update).
  2. National Asthma Education and Prevention Program Expert Panel Report 3 (EPR-3). Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 08-4051. 2007.
  3. Keeney GE, et al. Dexamethasone for acute asthma exacerbations in children: a meta-analysis. Pediatrics. 2014;133(3):493-499.
  4. Rowe BH, et al. Corticosteroid therapy for acute asthma. Respir Med. 2004;98(4):275-284.
  5. Cheuk DK, et al. A meta-analysis on intravenous magnesium sulphate for treating acute asthma. Arch Dis Child. 2005;90(1):74-77.
  6. British Thoracic Society/Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. 2019.
  7. Camargo CA Jr, et al. Emergency Medicine Network Investigators. Management of acute asthma in US emergency departments. Acad Emerg Med. 2003;10(4):364-372.
  8. UpToDate. Acute asthma exacerbations in children younger than 12 years: Emergency department management. 2024.

At a Glance

EvidenceStandard
Last UpdatedRecently

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines